PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20590599-8	2010	Other ligands (e.g. denopamine for beta(1); clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy.	dp	20-30	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	35-42
15608137-0	2005	Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.	dp	34-44	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	101-128
16916328-0	2006	Denopamine stimulates alveolar fluid clearance via cystic fibrosis transmembrane conductance regulator in rat lungs.	dp	0-10	CF transmembrane conductance regulator	Rattus norvegicus	51-102
16916328-6	2006	Although glibenclamide alone or CFTR(inh)-172 alone did not change basal alveolar fluid clearance, these CFTR inhibitors inhibited the effect of denopamine on alveolar fluid clearance.	dp	145-155	CF transmembrane conductance regulator	Rattus norvegicus	105-109
18779976-3	2009	A similar effect was produced by the selective beta(1)-AR agonist denopamine (1 microM) and by the unselective PDEs inhibitor IBMX (100 microM).	dp	66-76	adrenergic receptor, beta 1	Mus musculus	47-57
15608137-1	2005	Denopamine is one of the oral beta(1)-adrenoceptor-selective partial agonists.	dp	0-10	adrenoceptor beta 1	Homo sapiens	30-50
15608137-9	2005	The K(m) value of denopamine glucuronidation in recombinant UGT2B7 microsomes was close to those in human liver and jejunum microsomes.	dp	18-28	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	60-66
15608137-10	2005	The formation of denopamine glucuronidation by human liver, jejunum, and recombinant UGT2B7 microsomes was effectively inhibited by diclofenac, a known substrate for UGT2B7.	dp	17-27	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	85-91
15608137-10	2005	The formation of denopamine glucuronidation by human liver, jejunum, and recombinant UGT2B7 microsomes was effectively inhibited by diclofenac, a known substrate for UGT2B7.	dp	17-27	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	166-172
15608137-12	2005	These results demonstrate that the denopamine glucuronidation in human liver and intestine is mainly catalyzed by UGT2B7 and that glucuronidation of the alcoholic hydroxyl group, but not the phenolic hydroxyl group, occurs regioselectively in humans.	dp	35-45	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	114-120
7902433-1	1993	The pharmacological properties of the cardiotonic agent denopamine toward human beta-1 and beta-2 adrenergic receptors (AR) were assessed in a heterologous expression system.	dp	56-66	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	80-86
12487507-3	2002	In Japan, it has been reported that denopamine, which is an oral beta1-adrenoceptor selective agonist developed by the Japanese pharmaceutical industry (Tanabe Seiyaku), is effective in those refractory cases.	dp	36-46	adrenoceptor beta 1	Homo sapiens	65-83
9741531-0	1998	Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart.	dp	0-10	tumor necrosis factor	Mus musculus	149-176
9741531-4	1998	METHODS: In vitro: The effects of denopamine on lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha) production was studied in murine spleen cells.	dp	34-44	tumor necrosis factor	Mus musculus	75-102
9741531-4	1998	METHODS: In vitro: The effects of denopamine on lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha) production was studied in murine spleen cells.	dp	34-44	tumor necrosis factor	Mus musculus	104-113
9741531-9	1998	In the in vivo study treatment with denopamine significantly improved the survival of the animals (14 of 25 (56%) treated, vs 5 of 25 (20%) control mice), attenuated myocardial lesions, and suppressed TNF-alpha production (66.5+/-7.5 pg/mg of heart in treated mice vs 113.5+/-15.1 pg/mg of heart in control mice, mean+/-SE).	dp	36-46	tumor necrosis factor	Mus musculus	201-210
9741531-12	1998	CONCLUSIONS: These results suggest that denopamine may exert its beneficial effects, in part, by suppressing the production of TNF-alpha via beta1-adrenoceptors.	dp	40-50	tumor necrosis factor	Mus musculus	127-136
7589178-7	1995	These results suggested that in addition to activity as a beta 1-adrenoceptor agonist, denopamine also possessed activity as an alpha 1H-adrenoceptor-selective antagonist.	dp	87-97	adrenoceptor beta 1	Rattus norvegicus	58-77
7820101-0	1994	Binding of a catechol derivative of denopamine (T-0509) and N-tert-butylnoradrenaline (Colterol) to beta 1- and beta 2-adrenoceptors.	dp	36-46	beta-2 adrenergic receptor	Cavia porcellus	100-132
7902433-2	1993	In whole cells radiolabeled with the nonselective beta antagonist [125I]iodopindolol, denopamine displayed a 7-fold lower inhibition constant for the beta-1 than for the beta-2 AR.	dp	86-96	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	150-156
7902433-2	1993	In whole cells radiolabeled with the nonselective beta antagonist [125I]iodopindolol, denopamine displayed a 7-fold lower inhibition constant for the beta-1 than for the beta-2 AR.	dp	86-96	adrenoceptor beta 2	Homo sapiens	170-179
11422573-7	2001	Denopamine-induced dilations were significantly inhibited by 1 nmol betaxolol (a selective beta1-adrenoceptor antagonist), but it was not influenced by 1 nmol ICI 118,551 (a selective beta2-adrenoceptor antagonist).	dp	0-10	adrenoceptor beta 1	Rattus norvegicus	91-109
11422573-7	2001	Denopamine-induced dilations were significantly inhibited by 1 nmol betaxolol (a selective beta1-adrenoceptor antagonist), but it was not influenced by 1 nmol ICI 118,551 (a selective beta2-adrenoceptor antagonist).	dp	0-10	adrenoceptor beta 2	Rattus norvegicus	184-202
10531390-6	1999	In contrast to beta(2)AR, TM2 is a major determinant that beta(1)-selective agonists such as denopamine and T-0509 bound the beta(1)AR with high affinity.	dp	93-103	adrenoceptor beta 1	Homo sapiens	125-134
7902433-3	1993	Similarly, denopamine exhibited a 7-fold greater potency to stimulate the adenylyl cyclase activity in cells expressing the beta-1 AR than in cells expressing the beta-2 subtype, which confirmed the subtype selectivity of this drug.	dp	11-21	adrenoceptor beta 1	Homo sapiens	124-133
7902433-1	1993	The pharmacological properties of the cardiotonic agent denopamine toward human beta-1 and beta-2 adrenergic receptors (AR) were assessed in a heterologous expression system.	dp	56-66	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	91-97
7902433-3	1993	Similarly, denopamine exhibited a 7-fold greater potency to stimulate the adenylyl cyclase activity in cells expressing the beta-1 AR than in cells expressing the beta-2 subtype, which confirmed the subtype selectivity of this drug.	dp	11-21	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	163-169
7902433-5	1993	The extent of beta-1 AR desensitization induced by denopamine was then compared with that induced by the full agonist isoproterenol.	dp	51-61	adrenoceptor beta 1	Homo sapiens	14-23
2576812-9	1989	In this case, denopamine might have beta 2-agonist effect to dilate pulmonary vasculature, or have secondary effect to increase PO2 by the improvement of cardiac function.	dp	14-24	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	36-42
7902433-7	1993	A 24-hr pretreatment with denopamine produced a time-dependent reduction in the number of beta-1 AR with a rate of down-regulation slower than that produced by isoproterenol.	dp	26-36	adrenoceptor beta 1	Homo sapiens	90-99
7902433-8	1993	These data therefore indicate that denopamine is a beta-1 adrenergic selective agonist with low intrinsic activity that is less prone than full agonists to cause desensitization.	dp	35-45	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	51-57
8096549-0	1993	Efficacy of denopamine, a beta 1 adrenoceptor agonist, in preventing coronary artery spasm.	dp	12-22	adrenoceptor beta 1	Homo sapiens	26-45
8096549-1	1993	The selective beta 1 adrenoceptor agonist denopamine was studied for its effectiveness in abolishing active vasospastic angina in 10 patients without obstructive coronary artery stenosis.	dp	42-52	adrenoceptor beta 1	Homo sapiens	14-33
1357914-1	1992	Denopamine is an orally active beta 1 agonist whose cardiovascular action in the newborn is unknown.	dp	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	31-37
1354251-6	1992	In contrast, denopamine was a partial selective beta-1 adrenoceptor agonist (Emax = 0.75-0.85).	dp	13-23	adrenoceptor beta 1	Homo sapiens	48-67
34529322-5	2022	In addition, following 3 compounds were identified as inhibitors for Spike/ACE2: Denopamine, bometolol, and rotigaptide.	dp	81-91	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	69-74
34529322-5	2022	In addition, following 3 compounds were identified as inhibitors for Spike/ACE2: Denopamine, bometolol, and rotigaptide.	dp	81-91	angiotensin converting enzyme 2	Homo sapiens	75-79
34529322-7	2022	While the concentration-dependent inhibition of the ritonavir, rotigaptide, and cefotiam was observed for the main protease; denopamine was effective at the inhibition of Spike/ACE2 binding.	dp	125-135	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	171-176
34529322-7	2022	While the concentration-dependent inhibition of the ritonavir, rotigaptide, and cefotiam was observed for the main protease; denopamine was effective at the inhibition of Spike/ACE2 binding.	dp	125-135	angiotensin converting enzyme 2	Homo sapiens	177-181
2614668-4	1989	In order to extract the DP from the serum, a disposable solid extraction column (Sep-Pak cartridge, C-18) was used.	dp	24-26	Bardet-Biedl syndrome 9	Homo sapiens	100-104
2564629-1	1989	Prenalterol (beta 1-agonist), denopamine (beta 1-agonist), and zinterol (beta 2-agonist) were partial agonists of adenylate cyclase (AC) stimulation in human ventricular myocardium obtained from nonfailing chambers whose beta 1/beta 2 receptor subtype ratio was approximately 80/20.	dp	30-40	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	42-48
2564629-1	1989	Prenalterol (beta 1-agonist), denopamine (beta 1-agonist), and zinterol (beta 2-agonist) were partial agonists of adenylate cyclase (AC) stimulation in human ventricular myocardium obtained from nonfailing chambers whose beta 1/beta 2 receptor subtype ratio was approximately 80/20.	dp	30-40	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	42-48
2564629-7	1989	Moreover, in preparations from failing heart, the component of denopamine stimulation that was inhibited by 10(-7) M betaxolol (beta 1 component) was reduced by 77% (p less than 0.05).	dp	63-73	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	128-134
2829921-4	1988	Under these conditions, the increases in heart rate and tissue c-AMP levels by denopamine were significantly less than those by isoproterenol.	dp	79-89	cathelicidin antimicrobial peptide	Cavia porcellus	63-68
2829921-8	1988	The above differences in the effects on c-AMP levels and protein phosphorylation between denopamine and isoproterenol may be causally related to the differences in their pharmacological properties such as the weaker arrhythmogenicity and comparatively less marked relaxation effect of denopamine compared with isoproterenol in the presence of similar cardiotonic effects.	dp	89-99	cathelicidin antimicrobial peptide	Cavia porcellus	40-45
2876788-6	1986	In nonfailing myocardium, beta 1 responses predominated, as the selective beta 1 agonist denopamine produced a response that was 66% of the total contractile response of isoproterenol.	dp	89-99	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	74-80
2865114-6	1985	Furthermore, a high degree of stereoselective resistance of the alcoholic O-glucuronide of denopamine to hydrolysis by beta-glucuronidase was observed.	dp	91-101	glucuronidase, beta	Rattus norvegicus	119-137
2859176-3	1985	4"-O-Demethylated (M-1), 3"-O-demethylated (iso-M-1), and 3-hydroxylated (M-4) metabolites of denopamine were formed by incubation of denopamine with the rat liver microsomal fraction containing the NADPH-generating system.	dp	94-104	cholinergic receptor, muscarinic 4	Rattus norvegicus	74-77
2859176-5	1985	3-Methoxydenopamine (M-2) and 3-hydroxy-4-O-methyldenopamine (iso-M-2) were formed via the catechol intermediate M-4, when denopamine was incubated with the rat liver 9000g supernatant fraction in the presence of the NADPH-generating system and S-adenosyl-L-methionine.	dp	9-19	cholinergic receptor, muscarinic 4	Rattus norvegicus	113-116